Breast cancer, regarded as the “killer of beauty,” is a malignant tumor that severely threatens women’s health, with an increasing incidence year by year. Antibody-drug conjugates (ADC), as a new type of therapeutic drug, have become a hot research topic in the field of breast cancer due to their advantages of “high efficacy and low … Read more
*For reference by medical professionals only Antibody-drug conjugates (ADCs) have become a new hotspot in the field of anti-tumor therapy, with explorations in the treatment of breast cancer, lung cancer, gastric cancer, colorectal cancer, and other types of cancer. With the approval and clinical entry of drugs such as Trastuzumab Deruxtecan, Ado-trastuzumab emtansine, and Enfortumab … Read more
iNature Cold exposure therapy (CE) is a low-cost, non-invasive treatment for malignant tumors. When the body is exposed to a cold environment, it activates the thermogenic metabolism of brown adipose tissue (BAT), quickly inducing tumor starvation and inhibiting tumor growth. The microenvironmental changes caused by CE can further complement conventional treatments (such as radiotherapy and … Read more
Source Qian Zhang, Jiaxing Wang, Yanjun Ding, et al. Inhibition of Breast Cancer Cells by Novel Nanoparticles Combined with Low-Intensity Focused Ultrasound. Chinese Journal of Medical Imaging, 2020, 28(12): 907-911+917 Abstract Objective To explore the ability of the phase-change nanoparticles (Ce6@PFP/PLGA NPs) loaded with the sonosensitizer Chlorin e6 (Ce6) and perfluoropentane (PFP) combined with low-intensity … Read more
Expert Commentary Professor Yuan Zhongyu Department of Internal Medicine, Sun Yat-sen University Cancer Prevention and Treatment Center Chief Physician, MD, Doctoral Supervisor Engaged in clinical and research work on breast cancer for many years, has presided over and participated in over 20 clinical studies, involved in several research projects such as the National 863 Program … Read more
Expert Commentary Professor Feng Jifeng Chief Physician, Professor, Doctoral Supervisor Secretary of the Party Committee, Jiangsu Provincial Cancer Hospital/Nanjing Medical University Affiliated Cancer Hospital Member of the Expert Committee on Rational Drug Use, National Health Commission Council Member of the Chinese Medical Association, Member of the Internal Medicine Group of the Oncology Branch Vice President … Read more
Antibody-drug conjugates (ADC) are a novel type of medication that couples monoclonal antibodies, which specifically recognize cancer cell surface antigens, with cytotoxic chemotherapy drugs through specific linkers, exerting a significant tumor-killing effect. Currently, 15 ADC drugs, represented by trastuzumab emtansine (T-DM1) and trastuzumab deruxtecan (T-DXd, DS-8201), have been approved globally, significantly changing the treatment landscape … Read more
As early as 1913, during the 17th International Medical Congress, Professor Paul Ehrlich proposed the concept of the “magic bullet”, using monoclonal antibodies to specifically deliver cytotoxic drugs to tumor cells, thereby achieving the goal of killing tumor cells. With the development of monoclonal antibody production technology and the exploration of antibody conjugates, antibody-drug conjugates … Read more
This issue’s illustrations are from the article “CA 15-3-specific molecularly imprinted polymer nanoparticles-based voltammetric sensor for breast cancer monitoring” published on February 16, 2025, in Talanta (IF 5.6). 1. CA 15-3 specific nano molecularly imprinted polymers (nanoMIPs) have been developed and used as recognition sites for CA 15-3 detection; 2. The combination of nanoMIPs with … Read more
Click the blue text to follow us! From December 7 to 10, 2021, the 44th San Antonio Breast Cancer Symposium (SABCS) was grandly held. At this conference, updated follow-up data from the TEXT and SOFT studies over 13 years [1] were presented, along with the results of four randomized controlled trials (ABCSG 12, TEXT, SOFT, … Read more